Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP lessened its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 78.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,915 shares of the biotechnology company’s stock after selling 39,173 shares during the quarter. Two Sigma Investments LP’s holdings in Ascendis Pharma A/S were worth $1,503,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Virtus ETF Advisers LLC raised its stake in shares of Ascendis Pharma A/S by 3.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 100 shares during the last quarter. Legato Capital Management LLC raised its stake in shares of Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $28,000. Finally, Blue Trust Inc. raised its stake in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares during the last quarter.

Ascendis Pharma A/S Stock Down 0.7%

Shares of Ascendis Pharma A/S stock opened at $174.40 on Wednesday. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The business’s fifty day simple moving average is $157.71 and its 200-day simple moving average is $145.57. The firm has a market cap of $10.63 billion, a PE ratio of -24.56 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Evercore ISI raised their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, May 2nd. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Wedbush lifted their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $216.73.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.